The ‘boom’ of new anti-obesity medications is undeniable, brutal, and unprecedented. It’s curious because, although I just used three superlative and exaggerated adjectives, I’ve likely understated it. Ozempic and other GLP-1 agonists have no real precedents, and that’s breaking the rules of the game. The Legal Loophole The best example is that, since last year … Continue reading The Ozempic boom is so massive that US pharmacies have decided to do something unprecedented: start manufacturing it themselves